The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 3 study of anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in relapsed or refractory cutaneous T-cell lymphoma (CTCL).
Youn H. Kim
Consultant or Advisory Role - Kyowa Hakko Kirin
Research Funding - Kyowa Hakko Kirin
Martine Bagot
No relevant relationships to disclose
Herbert Aaron Eradat
No relevant relationships to disclose
Kenneth Robert Carson
No relevant relationships to disclose
John P. Greer
No relevant relationships to disclose
Ellen J. Kim
No relevant relationships to disclose
Timothy Kuzel
Research Funding - Kyowa Hakko Kirin
Lauren C Hughey
Research Funding - Kyowa Hakko Kirin
Brian Poligone
No relevant relationships to disclose
Frederick Lansigan
No relevant relationships to disclose
Pier Luigi Zinzani
No relevant relationships to disclose
Lisa M Grandinetti
No relevant relationships to disclose
Pierluigi Porcu
Employment or Leadership Position - US Cutaneous Lymphoma Consortium (U)
Andrei R. Shustov
No relevant relationships to disclose
Neil J Korman
Research Funding - Kyowa Hakko Kirin
Ahmad Halwani
No relevant relationships to disclose
Lubomir Sokol
No relevant relationships to disclose
Madeleine Duvic
Consultant or Advisory Role - Kyowa Hakko Kirin
Research Funding - Kyowa Hakko Kirin